Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Authors Mylla Boso AL, Gasperi E, Fernandes L, Costa VP, Alves M
Received 4 September 2019
Accepted for publication 4 November 2019
Published 14 January 2020 Volume 2020:14 Pages 103—111
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Ana Luiza Mylla Boso, Erica Gasperi, Leticia Fernandes, Vital Paulino Costa, Monica Alves
Department of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
Correspondence: Ana Luiza Mylla Boso
Department of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas, Cidade Universitária Zeferino Vaz - Barão Geraldo, Campinas, SP 13083-970, Brazil
Tel/Fax +55-19 3521 7396
Purpose: Chronic topical treatment for glaucoma may lead to Ocular Surface Disease (OSD). This study aimed to evaluate: (1) the prevalence of OSD in glaucoma patients under topical treatment, quantifying symptoms and objective ocular surface parameters and (2) the impact of ocular surface treatment on OSD and IOP control.
Methods: Patients with primary open angle or primary angle closure glaucoma under topical treatment for at least 6 months were enrolled in the study. Patients underwent symptom screening with the ocular surface disease index (OSDI) questionnaire, assessment of objective ocular surface parameters, ocular surface staining and Schirmer test. A treatment for OSD with eyelid hygiene, fluorometholone acetate 0.1%, preservative-free lubricants, free-acid supplementation and oral tetracyclin derivate was started, and the same evaluation was performed.
Results: In our sample (n=19), 73.68% of the patients reported severe symptoms of dry eye disease, with OSDI scores higher than 33 at baseline. Tear film instability was found in 50% of patients, while 23.53% had severe meibomian gland abnormalities. Fluorescein and lissamine green stainings were abnormal in 88.24% and 82.35% of patients, respectively. After ocular surface treatment, statistically significant improvement was found in best-corrected visual acuity (p=0.0003), OSDI score (p< 0.0001), bulbar redness (p=0.0196) and fluorescein staining (p< 0.0001.) Mean IOP following OSD treatment reduced − 1.59 mmHg from baseline in the left eye (p=0.0510).
Conclusion: The prevalence of OSD signs and symptoms was high in glaucoma patients under medical treatment. Short-term OSD treatment may improve ocular surface disease and IOP control, with no need to discontinue glaucoma medications.
Keywords: ocular surface disease, glaucoma, preservative, keratograph, benzalkonium chloride
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]